FDA
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners
-
-
-
-
-
-
-
4DMT to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical T
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) Reports Positive Data from Phase 2 Trial of Intravitreal 4D-150
-
-
-
-
-
-
-
4D Molecular (FDMT) Reports Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Trial
-
-
-
-
-
-
-
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
-
-
-
-
-
-
-
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

